All In Biotech

Drug Trial Radar · NCT01619813

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Aug 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Dec 14, 2012

Primary completion

Apr 26, 2016

Study completion May 20, 2016

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
Collaborators
Oncolytics Biotech
First posted
Jun 14, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if giving Reolysin in combination with docetaxel and prednisone can offer better results than standard therapy with docetaxel and prednisone.

Conditions

  • Prostate Cancer

Interventions

  • Docetaxel, Reolysin and PrednisoneDrug

    Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.

  • Docetaxel and PrednisoneDrug

    Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease ProgressionTime frame: 12 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • BCCA - Abbotsford Centre

    Abbotsford British Columbia, British Columbia, Canada

  • BCCA - Cancer Centre for the Southern Interior

    Kelowna, British Columbia, Canada

  • BCCA - Fraser Valley Cancer Centre

    Surrey, British Columbia, Canada

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Cancer Centre of Southeastern Ontario at Kingston

    Kingston, Ontario, Canada

  • London Regional Cancer Program

    London, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.